Found: 39
Select item for more details and to access through your institution.
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 546, doi. 10.1002/hon.3112
- By:
- Publication type:
- Article
Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemia.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 487, doi. 10.1002/hon.3111
- By:
- Publication type:
- Article
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 463, doi. 10.1002/hon.3109
- By:
- Publication type:
- Article
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 323, doi. 10.1002/hon.3102
- By:
- Publication type:
- Article
Chemoresistance in acute myeloid leukemia: An alternative single‐cell RNA sequencing approach.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 499, doi. 10.1002/hon.3129
- By:
- Publication type:
- Article
Long‐term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 407, doi. 10.1002/hon.3131
- By:
- Publication type:
- Article
Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims database.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 354, doi. 10.1002/hon.3128
- By:
- Publication type:
- Article
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 363, doi. 10.1002/hon.3126
- By:
- Publication type:
- Article
COVID‐19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 555, doi. 10.1002/hon.3127
- By:
- Publication type:
- Article
Prognostic value of prognostic nutritional index on extranodal natural killer/T‐cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working Group.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 380, doi. 10.1002/hon.3124
- By:
- Publication type:
- Article
COVID‐19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 559, doi. 10.1002/hon.3121
- By:
- Publication type:
- Article
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 453, doi. 10.1002/hon.3123
- By:
- Publication type:
- Article
Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 535, doi. 10.1002/hon.3101
- By:
- Publication type:
- Article
Knockdown of let‐7b in leukemia associated macrophages inhibit acute myeloid leukemia progression.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 510, doi. 10.1002/hon.3120
- By:
- Publication type:
- Article
Safety and efficacy of SARS‐Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR‐T cell infusion.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 563, doi. 10.1002/hon.3119
- By:
- Publication type:
- Article
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 335, doi. 10.1002/hon.3118
- By:
- Publication type:
- Article
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 415, doi. 10.1002/hon.3117
- By:
- Publication type:
- Article
Efficacy and safety of PD‐1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 396, doi. 10.1002/hon.3116
- By:
- Publication type:
- Article
Lenalidomide treatment for recurrent adult T‐cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 389, doi. 10.1002/hon.3115
- By:
- Publication type:
- Article
Outcome and molecular measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia patients with MEF2D fusions.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 594, doi. 10.1002/hon.3114
- By:
- Publication type:
- Article
Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 343, doi. 10.1002/hon.3113
- By:
- Publication type:
- Article
Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 520, doi. 10.1002/hon.3100
- By:
- Publication type:
- Article
Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin‐dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 474, doi. 10.1002/hon.3110
- By:
- Publication type:
- Article
Distinguishing myelodysplastic syndromes with moderate‐to‐severe bone marrow fibrosis from triple‐negative primary myelofibrosis based on clinical and genetic covariates.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 598, doi. 10.1002/hon.3091
- By:
- Publication type:
- Article
The impact of CD56 expression in smoldering myeloma patients on early progression.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 587, doi. 10.1002/hon.3104
- By:
- Publication type:
- Article
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 424, doi. 10.1002/hon.3108
- By:
- Publication type:
- Article
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 371, doi. 10.1002/hon.3107
- By:
- Publication type:
- Article
Richter transformation in Chronic Lymphocytic Leukemia.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 293, doi. 10.1002/hon.3106
- By:
- Publication type:
- Article
Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 442, doi. 10.1002/hon.3105
- By:
- Publication type:
- Article
Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 583, doi. 10.1002/hon.3055
- By:
- Publication type:
- Article
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant‐ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 590, doi. 10.1002/hon.3103
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 291, doi. 10.1002/hon.3020
- Publication type:
- Article
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 571, doi. 10.1002/hon.2989
- By:
- Publication type:
- Article
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 301, doi. 10.1002/hon.3088
- By:
- Publication type:
- Article
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 578, doi. 10.1002/hon.3071
- By:
- Publication type:
- Article
Diagnostic relevance of 2‐[<sup>18</sup>F]‐FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 434, doi. 10.1002/hon.3085
- By:
- Publication type:
- Article
Molecular remission is an independent predictor of progression‐free survival in patients with Waldenström macroglobulinemia treated with chemo‐immunotherapy: Results from the FIL_BIOWM study.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 574, doi. 10.1002/hon.3082
- By:
- Publication type:
- Article
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 567, doi. 10.1002/hon.3080
- By:
- Publication type:
- Article
TAFRO syndrome: A disease that known is half cured.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 310, doi. 10.1002/hon.3075
- By:
- Publication type:
- Article